Merck & Co., Inc. - Product Pipeline Review - 2016

  • ID: 3674241
  • Company Profile
  • 388 pages
  • Global Markets Direct
  • Merck & Co., Inc.
1 of 4
Merck & Co., Inc. - Product Pipeline Review - 2016

Summary

‘Merck & Co., Inc. - Product Pipeline Review - 2016’, provides an overview of the Merck & Co., Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Merck & Co., Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Merck & Co., Inc.
- The report provides overview of Merck & Co., Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Merck & Co., Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Merck & Co., Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Merck & Co., Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Merck & Co., Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Merck & Co., Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Merck & Co., Inc. Snapshot

Merck & Co., Inc. Overview

Key Information

Key Facts

Merck & Co., Inc. - Research and Development Overview

Key Therapeutic Areas

Merck & Co., Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Merck & Co., Inc. - Pipeline Products Glance

Merck & Co., Inc. - Late Stage Pipeline Products

Merck & Co., Inc. - Clinical Stage Pipeline Products

Merck & Co., Inc. - Early Stage Pipeline Products

Merck & Co., Inc. - Drug Profiles

(elbasvir + grazoprevir)

asenapine maleate

bezlotoxumab

desloratadine

diquafosol tetrasodium

fosaprepitant dimeglumine

insulin glargine

narlaprevir

pembrolizumab

(actoxumab + bezlotoxumab)

(atorvastatin calcium + ezetimibe)

(ceftolozane sulfate + tazobactam sodium)

(cilastatin sodium + imipenem + relebactam)

(doravirine + lamivudine + tenofovir disoproxil fumarate)

actoxumab

anacetrapib

corifollitropin alfa

doravirine

fidaxomicin

letermovir

odanacatib

omarigliptin

posaconazole

solithromycin

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract

tedizolid phosphate

V-212

V-920

verubecestat

vibegron

vorinostat

(grazoprevir + MK-3682 + MK-8408)

BQ-123

dalotuzumab

elbasvir + grazoprevir + MK-3682

grazoprevir

lomerizine

lonafarnib

mirtazapine ODT

MK-1029

MK-2206

MK-2206 + selumetinib sulfate

MK-7622

MK-8521

MK-8628

samatasvir

temozolomide

V-114

MK-3682

vorapaxar sulfate

CB-618

insulin human

MK-0752

MK-1075

MK-1248

MK-2048

MK-2248

MK-4166

MK-7680

MK-8189

MK-8242

MK-8291

MK-8408

MK-8507

MK-8591

MK-8666

MK-8723

MK-8876

Monoclonal Antibody for Autoimmune Diseases

NB-1008

rituximab biosimilar

Small Molecule 1 for Human Cytomegalovirus Infection

Small Molecule 2 for Human Cytomegalovirus Infection

V-160

V-180

BNC-375

CB-027

chikungunya (viral like particles) vaccine

DORA-12

Drug to Inhibit 11Beta-HSD1 for Hypertension

ETP-142

GP-4

GRA-1

J8-CRM197

mDX-400

MK-0429

MK-1966

MK-4256

MK-8267

MK-8745

MK-8825

MK-8970

Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia

Monoclonal Antibody for Cancer

MRK-003

MRK-1777

MRLB-11055

Proteins for Cancer, Autoimmune and Inflammatory diseases

PTC-512

PTC-725

PTC-971

PyP-1

respiratory syncytial virus vaccine

SCH-412348

SCH-546738

Small Molecule 3 for Human Cytomegalovirus Infection

Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders

Small Molecule to Antagonize Glucagon Receptor for Type 2 Diabetes

Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Staphylococcus aureus Infection

Small Molecule to Inhibit ROMK for Hypertension and Heart Failure

Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis

Small Molecules for Undisclosed Indications

Small Molecules to Agonize GPR119 for Metabolic Disorders

Small Molecules to Agonize M1 for Alzheimer’s Disease

Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease

Small Molecules to Block Cav2.2 Channel for Chronic Pain

Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases

Small Molecules to Inhibit DGAT1

Small Molecules to Inhibit DHFR for Septicaemia

Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours

Small Molecules to Inhibit Prolyl Hydroxylase for Anemia

Small Molecules to Inhibit Renin for Hypertension

THPP-1

TROX-1

XEN-445

XL-499

Drug to Target GPCR for Undisclosed Indication

Kibdelomycin A

MK-8133

Monoclonal Antibodies for Undisclosed Indication

Monoclonal Antibody for Neurology

SCH-722984

Small Molecules to Antagonize Adenosine 2A receptor for Undisclosed Indication

Small Molecules to Inhibit Inositol Phosphorylceramide for Fungal Infections

Small Molecules to Inhibit IRAK4 for Inflammatory Diseases

Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation

Small Molecules to Inhibit NS5A for Hepatitis C

Small Molecules to Inhibit PPI for Undisclosed Indication

Undisclosed Biosimilars

Merck & Co., Inc. - Pipeline Analysis

Merck & Co., Inc. - Pipeline Products by Target

Merck & Co., Inc. - Pipeline Products by Route of Administration

Merck & Co., Inc. - Pipeline Products by Molecule Type

Merck & Co., Inc. - Pipeline Products by Mechanism of Action

Merck & Co., Inc. - Recent Pipeline Updates

Merck & Co., Inc. - Dormant Projects

Merck & Co., Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Merck & Co., Inc. - Company Statement

Merck & Co., Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Merck & Co., Inc., Key Information

Merck & Co., Inc., Key Facts

Merck & Co., Inc. - Pipeline by Indication, 2016

Merck & Co., Inc. - Pipeline by Stage of Development, 2016

Merck & Co., Inc. - Monotherapy Products in Pipeline, 2016

Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2016

Merck & Co., Inc. - Partnered Products in Pipeline, 2016

Merck & Co., Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2016

Merck & Co., Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Merck & Co., Inc. - Pre-Registration, 2016

Merck & Co., Inc. - Phase III, 2016

Merck & Co., Inc. - Phase II, 2016

Merck & Co., Inc. - Phase I, 2016

Merck & Co., Inc. - Preclinical, 2016

Merck & Co., Inc. - Discovery, 2016

Merck & Co., Inc. - Pipeline by Target, 2016

Merck & Co., Inc. - Pipeline by Route of Administration, 2016

Merck & Co., Inc. - Pipeline by Molecule Type, 2016

Merck & Co., Inc. - Pipeline Products by Mechanism of Action, 2016

Merck & Co., Inc. - Recent Pipeline Updates, 2016

Merck & Co., Inc. - Dormant Developmental Projects,2016

Merck & Co., Inc. - Discontinued Pipeline Products, 2016

Merck & Co., Inc., Subsidiaries

List of Figures

Merck & Co., Inc. - Pipeline by Top 10 Indication, 2016

Merck & Co., Inc. - Pipeline by Stage of Development, 2016

Merck & Co., Inc. - Monotherapy Products in Pipeline, 2016

Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2016

Merck & Co., Inc. - Partnered Products in Pipeline, 2016

Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2016

Merck & Co., Inc. - Pipeline by Top 10 Target, 2016

Merck & Co., Inc. - Pipeline by Top 10 Route of Administration, 2016

Merck & Co., Inc. - Pipeline by Top 10 Molecule Type, 2016

Merck & Co., Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll